medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2013, Number 01

<< Back Next >>

Ginecol Obstet Mex 2013; 81 (01)

Effect of hormone therapy with estrogens on oxidative stress and quality of life in postmenopausal women

Sánchez RMA, Zacarías FM, Arronte RA, Mendoza NVM

Language: Spanish
References: 44
Page: 11-22
PDF size: 445.47 Kb.


ABSTRACT

Background: Estrogen therapy has an antioxidant effect and improves quality of life. There is no report on estrogen therapy and quality of life in relation to oxidative stress.
Objective: To determine the effect of estrogen hormonal therapy on quality of life and oxidative stress in postmenopausal women.
Patients and methods: We carried out a controlled clinical trial including 111 perimenopausal women (40 to 60 years old) living in Mexico City. Women were assigned into three groups: 1) control group, 39 premenopausal women; 2) 33 postmenopausal women receiving oral conjugated estrogens and medroxyprogesterone (0.625 mg/d plus medroxyprogesterone 5 mg/d for 10 days); 3) 33 postmenopausal women taking placebo pills. We measured at baseline and at six months biochemical markers of oxidative stress: lipoperoxides by TBARS assay, erythrocyte superoxide dismutase (SOD) and glutathione peroxidase (GPx) and total antioxidant status (TAS) with Randox Laboratories, Ltd. kits. We also applied the World Health Organization Quality of Life, Brief (WHOQoL-Brief).
Results: Levels of lipoperoxides were higher in postmenopausal women with low quality of life vs premenopausal women with high quality of life (0.357 ± 0.06 vs 0.315 ± 0.04 µmol/L, p ‹ 0.05). Plasma lipoperoxides diminished in women taking hormonal therapy with low quality of life after six months of treatment (0.357 ± 0.06 vs 0.293 ± 0.08 µmol/L, p ‹ 0.01); also, the proportion of women in therapy with basal high lipoperoxides and quality of life average-low diminished (p ‹ 0.05). There were no differences in the other groups.
Conclusion: Estrogen therapy improves quality of life and reduces lipoperoxides as oxidative stress biomarker in postmenopausal women.


REFERENCES

  1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.

  2. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944.

  3. Grady D, Yaffe K, Kristof M, Lin F, et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med 2002;113:543-548.

  4. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.

  5. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.

  6. Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;(03):CD004143.

  7. Blumel JE, Casteio-Branco C, Binfa L, Gramegna G, et al. Quality of life after the menopause: a population study. Maturitas 2000;34:17-23.

  8. Guyatt GH, Veldhuyzen Van Zanten SJ, Feeny DH, Patrick DL. Measuring quality of live in clinical trials: a taxonomy and review. CMAJ 1989;140:1441-1448.

  9. Greendale GA, Lee NP. The menopause. Lancet 1999;353:571- 580.

  10. McKinley NM. The developmental and cultural contexts of objectified body consciousness: a longitudinal analysis of two cohorts of women. Dev Psychol 2006;42:679-687.

  11. Harman D. Free radical theory of aging. Mutat Res 1992;275:257-266.

  12. Mendoza-Núñez VM, Ruiz-Ramos M, Sánchez-Rodríguez MA, Retana-Ugalde R, Muñoz-Sánchez JL. Aging-related oxidative stress in healthy humans. Tohoku J Exp Med 2007;213:261-268.

  13. Pansini F, Mollica G, Bergamini CM. Management of the menopausal disturbances and oxidative stress. Curr Pharm Des 2005;11:2063-2073.

  14. Sánchez-Rodríguez MA, Zacarías-Flores M, Arronte-Rosales A, Correa-Muñoz E, Mendoza-Núñez VM. Menopause as risk factor for oxidative stress. Menopause 2012;19:361-367.

  15. lrie M, Miyata M, Kasai H. Depression and possible cancer risk due to oxidative DNA damage. J Psych Res 2005;39:553-560.

  16. D’Almeida V, Hipólide DC, Lobo LL, de Oliveira AC, et al. Melatonin treatment does not prevent decreases in brain glutathione levels induced by sleep deprivation. Eur J Pharmacol 2000;390:299-302.

  17. Diario Oficial de la Federación. Modificación a la Norma Oficial Mexicana NOM-015-SSA2-1994, Para la prevención, tratamiento y control de la diabetes. 18 de enero del 2001. Disponible en: http://www.salud.gob.mx/unidades/cdi/nom/ m015ssa24.html. Consultado Junio 20, 2010.

  18. Sánchez-Rodríguez M, Mendoza-Núñez VM, García-Sánchez A, González-González B, et al. Valores de referencia para poblaciones senecta y adulta de la Ciudad de México. Parámetros bioquímicos y hematológicos. Acta Bioquím Clín Latinoam 1998;32:397-405.

  19. Jentzsch AM, Bachmann H, Fürst P, Biesalski HK. Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 1996;20:251-256.

  20. González-Celis RAL, Sánchez-Sosa JJ. Efectos de un programa cognitivo-conductual para mejorar la calidad de vida en adultos mayores. Rev Mex Psicol 2003;20:43-58.

  21. Secretaría de Salud. Expectativa de vida en México, Dirección de Epidemiología DF. México: Secretaría de Salud, 2006.

  22. Hill K. The demography of menopause. Maturitas 1996;23:113-127.

  23. Velarde-Jurado E, Ávila-Figueroa C. Evaluación de la calidad de vida. Salud Publica Méx 2002;44:349-361.

  24. Urdaneta MJ, Cepeda de VM, Guerra VM, Baabel.ZN, Contreras BA. Calidad de vida en mujeres menopáusicas con y sin terapia de remplazo hormonal. Rev Chil Obstet Ginecol 2010;75:1.

  25. Abbey M, Owen A, Suzakawa M, Roach P, Nestel PJ. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas 1999;33:259-269.

  26. Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Bidzicska B, Milewicz A, et al. Serum lipid peroxide levels and erythrocyte glutathione peroxidase and superoxide dismutase activity in premenopausal and postmenopausal women. Gynecol Endocrinol 2001;15:298-303.

  27. Signorelü SS, Neri S, Sciacchitano S, Pino LD, et al. Behaviour some indicators of oxidative stress in postmenopausal and fertile women. Maturitas 2006;53:77-82.

  28. Moreau KL, DePaulis AR, Gavin KM, Seals DR. Oxidative stress contributes to chronic leg vasoconstriction in estrogen-deficient postmenopausal women. J Appl Physiol 2007;102:890-895.

  29. Agarwal A, Gupta S, Sekhon L, Shah R. Redox considerations in female reproductive function and assisted reproduction: from molecular mechanisms to health implications. Antioxid Redox Signal 2008;10:1375-1403.

  30. Xing D, Nozell S, Chen YF, Hage F, Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009;29:289-295.

  31. Leal M, Díaz J, Serrano E, Avellán J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol 2000;95:804-809.

  32. Avis NE, Colvin A, Bromberger JT, Hess R, et al. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women’s Health Across the Nation (SWAN). Menopause 2009;16:860-869.

  33. Hernández-Valencia M, Córdova-Pérez N, Basurto L, Saucedo R y col. Frecuencia de los síntomas del síndrome climatérico. Ginecol Obstet Méx 2010;78:232-237.

  34. Chedraui P, Blümel JE, Baron G, Belzares E, et al. Impaired quality of life among middle aged women: a multicentre Latin American study. Maturitas 2008;61:323-329.

  35. Tao M, Teng Y, Shao H, Wu P, Mills EJ. Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and metasynthesis. PLoS ONE 2011;6(9):e24661. doi:10.1371/joumal. pone.0024661.

  36. Welton AJ, Vickers MR, Kim J, Ford D, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190. doi:10.1136/ bmj.a1190.

  37. Téxon-Fernández O, Márquez-Celedonio FG. Calidad de vida en mujeres climatéricas con y sin terapia hormonal de reemplazo. Rev Med Inst Mex Seguro Soc 2006;44:541-545.

  38. Veerus P, Fischer K, Hovi SL, Karro H, et al. Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health 2008;8:5. doi: 10.1186/1472-6874-8-5.

  39. Subbiah MTR. Mechanisms of cardioprotection by estrogens. Proc Soc Exper Biol Med 1998;217:23-29.

  40. Scarpellini F, Sbracia M, Scarpellini L. Psychological stress and lipoperoxidation in iscarriage. Ann NY Acad Sci 1994;709:210- 213.

  41. Schneider RH, Nidich SI, Salerno JW, Sharma HM, et al. Lower lipid peroxide levels in practitioners of transcendental meditation program. Psychosom Med 1998;60:38-41.

  42. Johansen O, Brox J, Flaten MA. Placebo and nocebo responses, cortisol, and circulating betaendorphin. Psychosom Med 2003;65:786-790.

  43. Sharma H, Sen S, Singh A, Bhardwaj NK, et al. Sudarshan Kriya practitioners exhibit better antioxidant status and lower blood lactate levels. Biol Psychol 2003;63:281-291.

  44. Kumar S, Lata K, Mukhopadhyay S, Mukherjee TK. Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: a perspective. Biochim Biophys Acta 2010;1800:1127-1135.




2020     |     www.medigraphic.com